Multicenter, Single-Arm Exploratory Phase I Clinical Study on the Safety and Efficacy of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Participants With Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma is a PHASE1 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in DLBCL, CLL, FL, MCL, WM, MZL. SEO and diligence focus: BAFF-R CAR-T, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.